• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 4, 2015

View Archived Issues

Vernalis embracing specialty pharma evolution with Tuzistra nod in U.S.

LONDON – The commercial prospects of Vernalis plc are about to be transformed following FDA approval of its lead prescription cough-cold product, Tuzistra. Read More

Left to its own devices: Medicines Co. dual wins calm Angiomax angst

The Medicines Co. may have prospectively eased the pain of generic competition that looms for flagship product Angiomax (bivalirudin) – and may have helped stanch the money hemorrhage that would result – by winning FDA approval of two drug-device combo therapies: one for patients who need opioid analgesia in the hospital and another to control bleeding. Read More

Chairman, investors join in going-private bid for Wuxi valued at $3.2B

HONG KONG – In the same week that it started construction of the largest biological manufacturing facility in China, Wuxi Pharmatech Inc. also received a privatization proposal from its founder and chairman. Read More

B cells get into antitumor immunity

Much of the excitement in immuno-oncology has been focused on killer T cells and dendritic cells. But, Edgar Engleman told BioWorld Today, "the immune system is designed to work as a team. . . . There is cooperation among the different branches of the armed services, as it were." Read More

Competition breeds biosimilar discounts the market can't ignore

A recent bidding war on a government tender in Norway for an infliximab biosimilar resulted in a 69 percent discount from the innovator and a rapid market uptake of the follow-on, proving that physicians and patients will flock to a biosimilar – if the price is right. Read More

Exelixis and Nektar gain ground, beat expectations

a href="https://cortellis.thomsonreuterslifesciences.com/ngg/qsearch/Exelixis%0D" target="_blank">Exelixis Inc. shares (NASDAQ:EXEL) climbed as much as 14 percent Friday on better-than-expected first quarter earnings, halved R&D costs and the hope that cabozantinib, which fizzled in a pivotal study for prostate cancer, would blaze brighter in METEOR, a phase III study in metastatic renal cell carcinoma (mRCC) reporting top-line data by the end of the second quarter or early in the third quarter. Read More

Financings

Northwest Biotherapeutics Inc., of Bethesda, Md., closed on the $28.5 million second tranche of a $40 million investment from Woodford investment funds in the UK. Woodford first invested $25 million in November 2014. Read More

Stock movers

Read More

Other news to note

Tamir Biotechnology Inc., of San Diego, offered an update on its Ebola antiviral therapy program. Read More

In the clinic

Celgene Corp., of Summit, N.J., reported results from a pre-specified secondary endpoint analysis of MDS-005, a randomized, placebo-controlled phase III study of Revlimid (lenalidomide) compared with placebo in patients with non-del-5q myelodysplastic syndromes. Read More

Pharma: Other news to note

Eisai Inc., of Woodcliff Lake, N.J., said it entered a settlement with Glenmark Pharmaceutials Ltd., of Mumbai, India, to resolve the patent litigation relating to Eisai's Banzel (rufinamide) in the U.S. Read More

Appointments and advancements

Blend Therapeutics Inc., of Watertown, Mass., appointed Drew Fromkin president and CEO. Read More

Bench Press: BioWorld looks at translational medicine

Researchers from Duke University have identified a method to potentially separate motor symptoms of the Parkinson's disease (PD) drug L-dopa from its side effects. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • Incurix describes new c-Myc inhibitors

    BioWorld Science
    Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe